Skip to main content
. 2022 Aug 30;14(9):1917. doi: 10.3390/v14091917

Figure 1.

Figure 1

Experimental design, survival and clinical evaluation after immunisation and challenge. (a) Experimental design: pigs underwent quarantine for at least 21 days prior to the start of the study. DPI 0: pigs were immunised with ASFV-Kenya-IX-1033-ΔCD2 or PBS; DPI 31: pigs were challenged with ASFV-Kenya-IX-1033. The experiment was terminated on DPI 51. (b) Kaplan–Meier survival curve after challenge with wildtype ASFV-Kenya-IX-1033 in animals after immunisation with ASFV-Kenya-IX-1033-ΔCD2 (green) or PBS (blue) and challenge with ASFV-Kenya-IX-1033. Days post challenge (DPC). (c) Cumulative clinical scores in animals after immunisation with ASFV-Kenya-IX-1033-ΔCD2 (green) or PBS (blue) and challenge with ASFV-Kenya-IX-1033. (d) Rectal temperatures in animals after immunisation with ASFV-Kenya-IX-1033-ΔCD2 (green) or PBS (blue) and challenge with ASFV-Kenya-IX-1033.